Tags

Type your tag names separated by a space and hit enter

A Comprehensive Updated Review on SARS-CoV-2 and COVID-19.
J Clin Pharmacol. 2020 08; 60(8):954-975.JC

Abstract

This literature review aims to provide a comprehensive current summary of the pathogenesis, clinical features, disease course, host immune responses, and current investigational antiviral and immunomodulatory pharmacotherapies to facilitate the development of future therapies and measures for prevention and control.

Links

PMC Free PDF

Authors+Show Affiliations

Ren YR
Division of Inflammation and Immune Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland, USA.
Golding A
Division of Rheumatology and Transplant Medicine, Office of Immunology and Inflammation, Office of New Drugs, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland, USA.
Sorbello A
Office of Translational Sciences, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland, USA.
Ji P
Division of Inflammation and Immune Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland, USA.
Chen J
Division of Inflammation and Immune Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland, USA.
Saluja B
Division of Inflammation and Immune Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland, USA.
Witzmann K
Office of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland, USA.
Arya V
Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland, USA.
Reynolds KS
Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland, USA.
Choi SY
Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland, USA.
Nikolov NP
Division of Rheumatology and Transplant Medicine, Office of Immunology and Inflammation, Office of New Drugs, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland, USA.
Sahajwalla C
Division of Inflammation and Immune Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, FDA, Silver Spring, Maryland, USA.

MeSH

Antiviral AgentsBetacoronavirusCOVID-19Coronavirus InfectionsHumansImmunotherapyPandemicsPneumonia, ViralSARS-CoV-2COVID-19 Drug Treatment

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32469437

Citation

Ren, Yunzhao R., et al. "A Comprehensive Updated Review On SARS-CoV-2 and COVID-19." Journal of Clinical Pharmacology, vol. 60, no. 8, 2020, pp. 954-975.
Ren YR, Golding A, Sorbello A, et al. A Comprehensive Updated Review on SARS-CoV-2 and COVID-19. J Clin Pharmacol. 2020;60(8):954-975.
Ren, Y. R., Golding, A., Sorbello, A., Ji, P., Chen, J., Saluja, B., Witzmann, K., Arya, V., Reynolds, K. S., Choi, S. Y., Nikolov, N. P., & Sahajwalla, C. (2020). A Comprehensive Updated Review on SARS-CoV-2 and COVID-19. Journal of Clinical Pharmacology, 60(8), 954-975. https://doi.org/10.1002/jcph.1673
Ren YR, et al. A Comprehensive Updated Review On SARS-CoV-2 and COVID-19. J Clin Pharmacol. 2020;60(8):954-975. PubMed PMID: 32469437.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A Comprehensive Updated Review on SARS-CoV-2 and COVID-19. AU - Ren,Yunzhao R, AU - Golding,Amit, AU - Sorbello,Alfred, AU - Ji,Ping, AU - Chen,Jianmeng, AU - Saluja,Bhawana, AU - Witzmann,Kimberly, AU - Arya,Vikram, AU - Reynolds,Kellie S, AU - Choi,Su-Young, AU - Nikolov,Nikolay P, AU - Sahajwalla,Chandrahas, Y1 - 2020/06/24/ PY - 2020/05/06/received PY - 2020/05/20/accepted PY - 2020/5/30/pubmed PY - 2020/7/24/medline PY - 2020/5/30/entrez KW - COVID-19 KW - SARS-CoV-2 KW - clinical characteristics KW - review KW - treatment SP - 954 EP - 975 JF - Journal of clinical pharmacology JO - J Clin Pharmacol VL - 60 IS - 8 N2 - This literature review aims to provide a comprehensive current summary of the pathogenesis, clinical features, disease course, host immune responses, and current investigational antiviral and immunomodulatory pharmacotherapies to facilitate the development of future therapies and measures for prevention and control. SN - 1552-4604 UR - https://www.unboundmedicine.com/medline/citation/32469437/A_Comprehensive_Updated_Review_on_SARS_CoV_2_and_COVID_19_ DB - PRIME DP - Unbound Medicine ER -